CYP-001 is under clinical development by Cynata Therapeutics and currently in Phase I for Respiratory Failure. According to GlobalData, Phase I drugs for Respiratory Failure have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CYP-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CYP-001 overview
CYP-001 is under development for the treatment of steroid-resistant graft versus host disease, respiratory failure, renal transplantation (renal), acute respiratory distress syndrome associated with coronavirus disease 2019 (COVID-19). It is off-the-shell ipSC derived MSC. The therapeutic candidate is administered as an intravenous infusion. It is developed based on Cymerus platform stem cell technology.
See Also:
Cynata Therapeutics overview
Cynata Therapeutics is a stem cell and regenerative medicine company. It develops and commercializes Cymerus, a stem cell platform technology used for the production of mesenchymal stem cells (MSCs) for human therapeutic use. Its proprietary technology platform utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor for generating mesen chymo angioblasts (MCAs) in manufacturing the Cymerus MSC therapeutic products for the treatment of osteoarthritis, brain cancer and melanoma, Crohn’s disease, asthma, acute respiratory distress syndrome and heart attack. Its lead MSC product candidate CYP-001 is used for the prevention and treatment of Graft-versus-host-disease (GvHD). The company has operations in Ireland and, the US. Cynata Therapeutics is headquartered in Melbourne, Carlton, Australia.
For a complete picture of CYP-001’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
